Teva Pharmaceutical Industries Limited (TLV:TEVA)
Israel
· Delayed Price · Currency is ILS · Price in ILA 6,186.00
+211.00 (3.53%)
Feb 20, 2025, 5:24 PM IDT
TLV:TEVA Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 16,544 | 15,846 | 14,925 | 15,878 | 16,659 | Upgrade
|
| Revenue Growth (YoY) | 4.40% | 6.17% | -6.00% | -4.69% | -1.35% | Upgrade
|
| Cost of Revenue | 8,481 | 8,200 | 7,952 | 8,284 | 8,933 | Upgrade
|
| Gross Profit | 8,063 | 7,646 | 6,973 | 7,594 | 7,726 | Upgrade
|
| Selling, General & Admin | 3,702 | 3,498 | 3,445 | 3,528 | 3,671 | Upgrade
|
| Research & Development | 998 | 953 | 838 | 967 | 997 | Upgrade
|
| Other Operating Expenses | -9 | 15 | 28 | 20 | 3 | Upgrade
|
| Operating Expenses | 4,691 | 4,466 | 4,311 | 4,515 | 4,671 | Upgrade
|
| Operating Income | 3,372 | 3,180 | 2,662 | 3,079 | 3,055 | Upgrade
|
| Interest Expense | -1,002 | -1,029 | -930 | -891 | -901 | Upgrade
|
| Interest & Investment Income | 86 | 68 | 10 | - | 104 | Upgrade
|
| Earnings From Equity Investments | 1 | 2 | 21 | 9 | 138 | Upgrade
|
| Currency Exchange Gain (Loss) | -17 | -30 | 16 | -7 | 26 | Upgrade
|
| Other Non Operating Income (Expenses) | -48 | -66 | -62 | -69 | -63 | Upgrade
|
| EBT Excluding Unusual Items | 2,392 | 2,125 | 1,717 | 2,121 | 2,359 | Upgrade
|
| Merger & Restructuring Charges | -74 | -111 | -146 | -133 | -120 | Upgrade
|
| Impairment of Goodwill | -1,280 | -700 | -2,045 | - | -4,628 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -90 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 17 | 28 | 64 | 58 | 19 | Upgrade
|
| Asset Writedown | -1,275 | -378 | -402 | -584 | -1,918 | Upgrade
|
| Legal Settlements | -760 | -1,038 | -2,069 | -698 | -60 | Upgrade
|
| Other Unusual Items | -303 | -548 | -261 | -7 | 81 | Upgrade
|
| Pretax Income | -1,283 | -622 | -3,142 | 667 | -4,267 | Upgrade
|
| Income Tax Expense | 676 | -7 | -643 | 211 | -168 | Upgrade
|
| Earnings From Continuing Operations | -1,959 | -615 | -2,499 | 456 | -4,099 | Upgrade
|
| Minority Interest in Earnings | 320 | 56 | 53 | -39 | 109 | Upgrade
|
| Net Income | -1,639 | -559 | -2,446 | 417 | -3,990 | Upgrade
|
| Net Income to Common | -1,639 | -559 | -2,446 | 417 | -3,990 | Upgrade
|
| Shares Outstanding (Basic) | 1,131 | 1,119 | 1,110 | 1,102 | 1,095 | Upgrade
|
| Shares Outstanding (Diluted) | 1,131 | 1,119 | 1,110 | 1,107 | 1,095 | Upgrade
|
| Shares Change (YoY) | 1.07% | 0.81% | 0.27% | 1.10% | 0.37% | Upgrade
|
| EPS (Basic) | -1.45 | -0.50 | -2.20 | 0.38 | -3.64 | Upgrade
|
| EPS (Diluted) | -1.45 | -0.50 | -2.20 | 0.38 | -3.64 | Upgrade
|
| Free Cash Flow | 749 | 842 | 1,042 | 236 | 638 | Upgrade
|
| Free Cash Flow Per Share | 0.66 | 0.75 | 0.94 | 0.21 | 0.58 | Upgrade
|
| Gross Margin | 48.74% | 48.25% | 46.72% | 47.83% | 46.38% | Upgrade
|
| Operating Margin | 20.38% | 20.07% | 17.84% | 19.39% | 18.34% | Upgrade
|
| Profit Margin | -9.91% | -3.53% | -16.39% | 2.63% | -23.95% | Upgrade
|
| Free Cash Flow Margin | 4.53% | 5.31% | 6.98% | 1.49% | 3.83% | Upgrade
|
| EBITDA | 4,431 | 4,333 | 3,970 | 4,409 | 4,612 | Upgrade
|
| EBITDA Margin | 26.78% | 27.34% | 26.60% | 27.77% | 27.68% | Upgrade
|
| D&A For EBITDA | 1,059 | 1,153 | 1,308 | 1,330 | 1,557 | Upgrade
|
| EBIT | 3,372 | 3,180 | 2,662 | 3,079 | 3,055 | Upgrade
|
| EBIT Margin | 20.38% | 20.07% | 17.84% | 19.39% | 18.34% | Upgrade
|
| Effective Tax Rate | - | - | - | 31.63% | - | Upgrade
|
| Advertising Expenses | - | - | - | 246 | 225 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.